Compare Gitlab Inc (GTLB) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gitlab Inc vs Nuwellis Inc — how do they compare? Gitlab Inc trades at $55.09 (market cap $8.92B), while Nuwellis Inc trades at $0.69 (market cap $2.20M). The key difference: Gitlab Inc is far larger — about 4054.5× Nuwellis Inc's market cap, and Gitlab Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gitlab Inc for 62 Days and Nuwellis Inc for 26 Days on average.
| GTLB | NUWE | |
|---|---|---|
Market Cap | $8.92B | $2.20M |
Volume | 4,716,893 | 121,544 |
Sector | Technology | Health |
52-Week High | $55.09 | $146.65 |
52-Week Low | $19.42 | $0.68 |
Typical Hold Time | 62 Days | 26 Days |
Enterprise Value | $7.66B | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GitLab (GTLB) trades at $53.56, up 3.02% with strong technical momentum as it approaches resistance at $54. The stock shows bullish moving average signals despite an overbought RSI. Fundamentally, revenue growth remains robust at 21.3% in Q2 2026 with consistent earnings beats, though profitability metrics like negative net income margin and ROE highlight ongoing challenges. Recent news highlights AI-driven product traction and raised guidance, fueling investor optimism.
Outlook: GitLab's AI integration and sales momentum support upside potential, but high valuation multiples and persistent cash burn pose risks. Analyst consensus is mixed with a $49.71 price target below current levels, suggesting cautious optimism amid execution and competitive pressures.
NUWE trades at $0.689, down 0.25% with a bearish technical signal despite oversold RSI readings. The company shows promising revenue growth (14% YoY in Q2 2026) and strong gross margins (69.69%), but faces significant profitability challenges with a -125.63% net income margin and negative cash flow. Recent news highlights console adoption growth and strategic expansions in pediatric care.
While NUWE's valuation metrics appear attractive (P/E 0.03, P/S 0.01), the company's persistent losses and negative cash flow present substantial risk. Analyst sentiment is mixed with a 50/50 buy/hold split. The stock offers speculative potential if management can achieve profitability, but requires careful risk assessment given current financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
